Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089590920> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3089590920 endingPage "92" @default.
- W3089590920 startingPage "85" @default.
- W3089590920 abstract "Abstract Objectives The Brazilian public health system does not cover pharmacotherapy for urge urinary incontinence (UUI). The aim of this study was to estimate the cost-effectiveness and budget impact of providing tolterodine, solifenacin, oxybutynin (OXY), darifenacin, and mirabegron for the treatment of UUI in Brazilian public health system. Methods A cost-effectiveness analysis with budget impact was performed. Six scenarios were assessed: in one scenario, all 5 therapeutic alternatives approved for coverage, and in the remaining 5 scenarios, only 1 alternative is approved for adoption for all patients. Clinical data were derived from a rapid systematic review conducted in several databases. One-way sensitivity analysis was also performed. The time horizon was 12 months. Results The cost-effectiveness analysis showed that patients treated with OXY had the lowest incremental cost-effectiveness ratio (ICER) per outcomes assessed (change in urinary incontinence episodes (UIE): R$1180.08; change in urge incontinence episodes: R$757.85 and change in micturition frequency: R$907.75), corresponding to a budget impact of R$17.9 billion over 5 years. The change in effectiveness measures was the parameter that most influenced the results of the ICER per patient-year. Conclusion The results of the study have shown that OXY and solifenacin had the lowest ICER per patient-year and the lowest budget impact when compared with other drugs." @default.
- W3089590920 created "2020-10-08" @default.
- W3089590920 creator A5003603176 @default.
- W3089590920 creator A5009468503 @default.
- W3089590920 creator A5029673130 @default.
- W3089590920 creator A5045428125 @default.
- W3089590920 creator A5070681970 @default.
- W3089590920 date "2020-12-01" @default.
- W3089590920 modified "2023-10-02" @default.
- W3089590920 title "Cost-Effectiveness Analysis and Budget Impact: Antimuscarinics and Mirabegron for the Treatment of Patients With Urge Urinary Incontinence: The Brazilian Public Health System Perspective" @default.
- W3089590920 cites W11809405 @default.
- W3089590920 cites W1602978258 @default.
- W3089590920 cites W1911361640 @default.
- W3089590920 cites W1995202401 @default.
- W3089590920 cites W2028181133 @default.
- W3089590920 cites W2034265241 @default.
- W3089590920 cites W2081270036 @default.
- W3089590920 cites W2082897746 @default.
- W3089590920 cites W2089190823 @default.
- W3089590920 cites W2096360296 @default.
- W3089590920 cites W2131173377 @default.
- W3089590920 cites W2137914036 @default.
- W3089590920 cites W2145072698 @default.
- W3089590920 cites W2158478797 @default.
- W3089590920 cites W2606434824 @default.
- W3089590920 cites W2618726866 @default.
- W3089590920 cites W2729515254 @default.
- W3089590920 cites W2766947181 @default.
- W3089590920 cites W2887535210 @default.
- W3089590920 cites W2902946292 @default.
- W3089590920 doi "https://doi.org/10.1016/j.vhri.2020.03.001" @default.
- W3089590920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33007721" @default.
- W3089590920 hasPublicationYear "2020" @default.
- W3089590920 type Work @default.
- W3089590920 sameAs 3089590920 @default.
- W3089590920 citedByCount "1" @default.
- W3089590920 countsByYear W30895909202022 @default.
- W3089590920 crossrefType "journal-article" @default.
- W3089590920 hasAuthorship W3089590920A5003603176 @default.
- W3089590920 hasAuthorship W3089590920A5009468503 @default.
- W3089590920 hasAuthorship W3089590920A5029673130 @default.
- W3089590920 hasAuthorship W3089590920A5045428125 @default.
- W3089590920 hasAuthorship W3089590920A5070681970 @default.
- W3089590920 hasBestOaLocation W30895909201 @default.
- W3089590920 hasConcept C126894567 @default.
- W3089590920 hasConcept C12713177 @default.
- W3089590920 hasConcept C142724271 @default.
- W3089590920 hasConcept C154945302 @default.
- W3089590920 hasConcept C177713679 @default.
- W3089590920 hasConcept C204787440 @default.
- W3089590920 hasConcept C2778164427 @default.
- W3089590920 hasConcept C2778531004 @default.
- W3089590920 hasConcept C2778941218 @default.
- W3089590920 hasConcept C41008148 @default.
- W3089590920 hasConcept C71924100 @default.
- W3089590920 hasConceptScore W3089590920C126894567 @default.
- W3089590920 hasConceptScore W3089590920C12713177 @default.
- W3089590920 hasConceptScore W3089590920C142724271 @default.
- W3089590920 hasConceptScore W3089590920C154945302 @default.
- W3089590920 hasConceptScore W3089590920C177713679 @default.
- W3089590920 hasConceptScore W3089590920C204787440 @default.
- W3089590920 hasConceptScore W3089590920C2778164427 @default.
- W3089590920 hasConceptScore W3089590920C2778531004 @default.
- W3089590920 hasConceptScore W3089590920C2778941218 @default.
- W3089590920 hasConceptScore W3089590920C41008148 @default.
- W3089590920 hasConceptScore W3089590920C71924100 @default.
- W3089590920 hasLocation W30895909201 @default.
- W3089590920 hasOpenAccess W3089590920 @default.
- W3089590920 hasPrimaryLocation W30895909201 @default.
- W3089590920 hasRelatedWork W2071059863 @default.
- W3089590920 hasRelatedWork W2223620698 @default.
- W3089590920 hasRelatedWork W2313053739 @default.
- W3089590920 hasRelatedWork W2323232114 @default.
- W3089590920 hasRelatedWork W2743658275 @default.
- W3089590920 hasRelatedWork W2784905695 @default.
- W3089590920 hasRelatedWork W2800137986 @default.
- W3089590920 hasRelatedWork W3155477964 @default.
- W3089590920 hasRelatedWork W3171971260 @default.
- W3089590920 hasRelatedWork W3203582714 @default.
- W3089590920 hasVolume "23" @default.
- W3089590920 isParatext "false" @default.
- W3089590920 isRetracted "false" @default.
- W3089590920 magId "3089590920" @default.
- W3089590920 workType "article" @default.